BR9507451A - Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo - Google Patents

Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo

Info

Publication number
BR9507451A
BR9507451A BR9507451A BR9507451A BR9507451A BR 9507451 A BR9507451 A BR 9507451A BR 9507451 A BR9507451 A BR 9507451A BR 9507451 A BR9507451 A BR 9507451A BR 9507451 A BR9507451 A BR 9507451A
Authority
BR
Brazil
Prior art keywords
amount
polypeptide
antigen together
standardized antigen
standardized
Prior art date
Application number
BR9507451A
Other languages
English (en)
Portuguese (pt)
Inventor
David A Hafler
Howard L Weiner
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of BR9507451A publication Critical patent/BR9507451A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
BR9507451A 1994-04-08 1995-04-07 Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo BR9507451A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
PCT/US1995/004120 WO1995027499A1 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Publications (1)

Publication Number Publication Date
BR9507451A true BR9507451A (pt) 1997-08-05

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507451A BR9507451A (pt) 1994-04-08 1995-04-07 Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo

Country Status (9)

Country Link
EP (1) EP0752880A4 (de)
JP (1) JPH09511745A (de)
AU (1) AU686797B2 (de)
BR (1) BR9507451A (de)
CA (1) CA2185353A1 (de)
HU (1) HUT74900A (de)
IL (1) IL113303A0 (de)
NO (1) NO964199L (de)
WO (1) WO1995027499A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
BR9509438A (pt) * 1994-10-25 1997-12-23 Immulogic Pharma Corp Composições e tratamento para a esclerose múltipla
SI0948358T2 (sl) * 1996-12-24 2012-03-30 Biogen Idec Inc Stabilne tekoče formulacije interferona
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
WO2001089557A2 (en) 2000-05-24 2001-11-29 The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services Methods for preventing strokes by inducing tolerance to e-selectin
CA2511209A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. Agent for treatment of pemphigoid
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
US20120082644A1 (en) * 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (ja) * 2013-11-11 2019-10-16 キッコーマン株式会社 経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
ES2190784T3 (es) * 1992-02-28 2003-08-16 Autoimmune Inc Supresion de enfermedades autoinmunes por antigenos espectadores.

Also Published As

Publication number Publication date
JPH09511745A (ja) 1997-11-25
EP0752880A1 (de) 1997-01-15
HUT74900A (en) 1997-02-28
IL113303A0 (en) 1995-07-31
EP0752880A4 (de) 2000-08-09
WO1995027499A1 (en) 1995-10-19
HU9602750D0 (en) 1996-11-28
AU2277695A (en) 1995-10-30
NO964199D0 (no) 1996-10-03
CA2185353A1 (en) 1995-10-19
NO964199L (no) 1996-10-03
AU686797B2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
BR9607317A (pt) Peptídios e composição farmacêutica
FI952900A7 (fi) Polypeptidi ja siitä valmistettu anti-HIV-aine
FI963185L (fi) Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi
FI972657A0 (fi) Proteiinien ja peptidien aerosoliformuloinnit
DE69233474D1 (de) Pharmazeutische Zusammensetzung enthaltend S-Nitrosoimmunoglobuline und Verwendung davon
IL116512A0 (en) Cyclic peptides their preparation and pharmaceutical compositions containing them
FI892727A7 (fi) Stabiloitu FGF-koostumus ja sen valmistus
FI943745L (fi) Koostumuksia ja menetelmiä proteiinin rakenteen määrityksiin
IL115484A (en) Polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
HU9802116D0 (en) 19-nor-d-vitamin compounds with biologically effect and pharmaceutical compositions containing them
IL110160A (en) Phosphopeptides their preparation and pharmaceutical compositions containing them
FI945619L (fi) Syklosporiinia sisältävät nestemäiset valmisteet ja menetelmä niiden valmistamiseksi
IL117349A0 (en) N-(3-benyofuranyl) urea-derivatives their preparation and pharmaceutical compositions containing them
BR9610821A (pt) Derivado de aminoácido uso de um composto e medicamento contendo o mesmo
BR9507452A (pt) Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
FI963196L (fi) Melanoomaspesifisten sytoksisten lymfosyyttien tunnistamia peptidejä ja niiden käyttö
MX9302927A (es) Nuevos peptidos, la preparacion y utilizacion de los mimos.
ATE204177T1 (de) Verwendung von substanz p antagonist im pharmazeutischer zusammensetzung
FI971427A7 (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
FI972757L (fi) Runsaasti hydroksiproliinia sisältävät proteiinit ja niitä sisältävät farmaseuttiset ja kosmeettiset koostumukset
FI905825A7 (fi) Amfifiiliset peptidit ja niiden käyttö
BR9607757A (pt) Vírus recombinante defectivo adenovírus utilização de um vírus e composição farmacêutica
DK439589D0 (da) Fluorsubstituerede 4'-demethylepipodophyllotoksinderivater samt farmaceutiske praeparater indeholdende samme
FI955123A7 (fi) Kolestyramiinia sisältävä koostumus ja menetelmä tämän valmistamiseksi
BR9604938A (pt) Vírus recombinante deficiente utilização deste vírus composição farmacêutica e célula de mamífero

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]